Markets
Business
Investing
Tech
Politics
CNBC TV
Watchlist
Investing Club
PRO

stocks Forest Laboratories Inc

  • picks_pans_badge.jpg
    Top Managers: Value Stocks Look Promising

    The recent gyrations in the markets may have scared some investors away, but two leading  portfolio managers say there are still plenty of value stocks to be snapped up.

  • One Giant Leap for MannKind

    Billionaire Alfred Mann must not have liked watching stock in the company bearing his name fall to another new low today in the wake of Eli Lilly giving up on inhaled insulin.

  • Analyst: Pfizer Should Buy Amgen or Wyeth

    I thought I was finished with the post-Pfizer analyst meeting reaction with yesterday's post, but when an extraordinarily bearish 77-page research note from Credit Suisse big pharma analyst Catherine Arnold arrived in my inbox this morning, I had to do one more installment. She thinks Pfizer should buy Wyeth or Amgen...

  • picks_pans_badge.jpg
    Directions For Investing In a Non-Directional Market

    Scott Richter has a set of directions for investors in a market that lacks direction: be selective; be defensive; and be very attentive to valuation.

  • drug_stocks.jpg
    Drug Stocks: Real Downers And At A Two-Year Low

    Yes, it was a big down day for equities, but I wanted to call attention to the fact that according to one of our resident stock gurus, Robert Hum, the Amex Pharmaceutical Index (you can see the 15 stocks that make up the so-called DRG here) closed at a two-year low today.

  • merck_logo.jpg
    Pharma Investors: Will Political Talk Scare Them Off?

    If or when you watch one of the presidential  debates count how many times the candidates say, "the drug companies." Of course, it depends on which party's debate you might be watching, but since I started paying attention to the race in recent weeks, I've taken notice how much those three words seem to be apart of boilerplate answers and statements...

  • genentech_logo_1.jpg
    Did Genentech Back Down or Backpedal?

    So, it didn't take long after my Genentech blog entry got posted yesterday for me to receive an email and a voicemail from a Genentech spokesperson requesting a "clarification" on my take regarding the latest chapter in the Avastin vs. Lucentis brouhaha. I think I'm being spun.

  • rodman_renshaw_card.jpg
    "Banking" On Holiday Gifts? I Can Say It's The Thought That Counts!

    Most of my PR and professional contacts send Christmas cards, but for the past two years the boutique Wall Street firm, Rodman & Renshaw, has sent me heavy metal piggy banks. I assume the company sends them to its clients as well.

  • Forest Lab Shares Fall as Earnings Miss Forecasts

    Forest Laboratories said Tuesday quarterly earnings fell 7 percent, hurt by a charge related to a product-licensing deal, and posted revenue that missed Wall Street expectations.

  • "The Noonday Demon" & "A Stone Boat" by Andrew Solomon
    Forest Labs: Celebrating A Real Family Affair

    In the "Sunday Styles" section of "The New York Times" the paper runs a very prestigious weekly feature known as "Vows". It's a relatively long write-up of someone's wedding and accompanied by pictures from the event. Yesterday, the Times highlighted the ceremony of Andrew Solomon and John Habich (for at least a few years now, The Times has included same-sex partnerships in its "Weddings/Celebrations").

  • M&A Watch: Where Private Equity May Look Next for Deals

    Mergers and acquisitions are headed for another record year, fueled by a seemingly endless cascade of private-equity money.  “I can’t think of anything that’s off limits,” says Michael Kelly, managing director at Hamilton Lane. "There are good companies in any industry."

  • CNBC's Domm: A Very Busy Week Ahead

    Financials and techs, two groups that pulled in the money last week, will be out in front of the news this week when earnings season is in full swing. Markets will also be watching key economic data, a parade of Fed speakers and whatever side show goes on when oil markets reopen, after last week's near six percent slide in crude.